Mesoporous Matrices as a Promising New Generation of Carriers for Multipolymorphic Active Pharmaceutical Ingredient Aripiprazole.
aripiprazole
crystallization
dissolution rate
drug carrier
mesopores
polymorphic forms
Journal
Molecular pharmaceutics
ISSN: 1543-8392
Titre abrégé: Mol Pharm
Pays: United States
ID NLM: 101197791
Informations de publication
Date de publication:
06 11 2023
06 11 2023
Historique:
medline:
7
11
2023
pubmed:
27
9
2023
entrez:
27
9
2023
Statut:
ppublish
Résumé
The enhancement of the properties (i.e., poor solubility and low bioavailability) of currently available active pharmaceutical ingredients (APIs) is one of the major goals of modern pharmaceutical sciences. Among different strategies, a novel and innovative route to reach this milestone seems to be the application of nanotechnology, especially the incorporation of APIs into porous membranes composed of pores of nanometric size and made of nontoxic materials. Therefore, in this work, taking the antipsychotic API aripiprazole (APZ) infiltrated into various types of mesoporous matrices (anodic aluminum oxide, native, and silanized silica) characterized by similar pore diameters (
Identifiants
pubmed: 37756382
doi: 10.1021/acs.molpharmaceut.3c00524
pmc: PMC10630940
doi:
Substances chimiques
Aripiprazole
82VFR53I78
Drug Carriers
0
Silicon Dioxide
7631-86-9
Pharmaceutical Preparations
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
5655-5667Références
Pharm Res. 2005 Dec;22(12):2121-33
pubmed: 16283568
J Nanosci Nanotechnol. 2012 Mar;12(3):2625-33
pubmed: 22755100
Pharmaceutics. 2020 Apr 22;12(4):
pubmed: 32331310
Pharmaceutics. 2021 Jul 12;13(7):
pubmed: 34371758
J Pharm Sci. 2002 Aug;91(8):1863-72
pubmed: 12115813
J Chem Phys. 2018 Aug 14;149(6):064501
pubmed: 30111133
Mol Pharm. 2016 Apr 4;13(4):1308-16
pubmed: 26981876
Phys Rev E Stat Phys Plasmas Fluids Relat Interdiscip Topics. 1996 Nov;54(5):5377-5390
pubmed: 9965723
Int J Nanomedicine. 2007;2(2):129-41
pubmed: 17722542
Nat Rev Drug Discov. 2021 Feb;20(2):101-124
pubmed: 33277608
J Chem Phys. 2017 May 28;146(20):203330
pubmed: 28571332
J Colloid Interface Sci. 2020 Sep 15;576:217-229
pubmed: 32417683
Sci Rep. 2021 Oct 12;11(1):20191
pubmed: 34642409
J Nanosci Nanotechnol. 2002 Dec;2(6):581-612
pubmed: 12908422
Colloids Surf B Biointerfaces. 2013 Jan 1;101:228-35
pubmed: 23010024
Profiles Drug Subst Excip Relat Methodol. 2012;37:1-29
pubmed: 22469315
J Chem Phys. 2005 Nov 15;123(19):194509
pubmed: 16321102
Mol Pharm. 2019 Apr 1;16(4):1742-1750
pubmed: 30848603
J Phys Chem Lett. 2022 Nov 10;13(44):10464-10470
pubmed: 36326602
Mater Sci Eng C Mater Biol Appl. 2014 Jan 1;34:78-85
pubmed: 24268236
Proc Natl Acad Sci U S A. 2003 Mar 4;100(5):2180-4
pubmed: 12604798
Phys Chem Chem Phys. 2016 Aug 24;18(34):23709-14
pubmed: 27510859
Adv Drug Deliv Rev. 2004 Feb 23;56(3):335-47
pubmed: 14962585
Acta Pharm Sin B. 2015 Sep;5(5):442-53
pubmed: 26579474
Molecules. 2018 Jul 14;23(7):
pubmed: 30011904
Mol Pharm. 2014 Mar 3;11(3):1032-41
pubmed: 24506163
Molecules. 2020 Oct 15;25(20):
pubmed: 33076274
Phys Chem Chem Phys. 2010 Nov 7;12(41):13798-803
pubmed: 20824257
Polim Med. 2018 Jul-Dec;48(2):77-82
pubmed: 30916495
J Chem Phys. 2017 Jun 7;146(21):214501
pubmed: 28595416
Bioimpacts. 2015;5(1):55-63
pubmed: 25901297
Mol Pharm. 2020 Mar 2;17(3):990-1000
pubmed: 31961694
J Pharm Sci. 2009 Jun;98(6):2010-26
pubmed: 19009597
Drug Discov Today. 2003 Dec 15;8(24):1112-20
pubmed: 14678737
Langmuir. 2023 Jan 10;39(1):533-544
pubmed: 36575053
J Phys Chem Lett. 2015 Sep 17;6(18):3708-12
pubmed: 26722745
Mol Pharm. 2017 Sep 5;14(9):3164-3177
pubmed: 28836790
Expert Opin Drug Deliv. 2016;13(1):93-108
pubmed: 26549623
Mol Pharm. 2019 Feb 4;16(2):856-866
pubmed: 30615456